Scotland is quietly becoming a testbed for a new approach to dementia: treat risk early, slow the underlying disease, and keep people independent for longer. At the heart of that shift is Aberdeen, where a cluster of companies and clinicians is starting to turn decades of neurodegeneration research into real‑world interventions.
This month, Aberdeen‑based TauRx reported fresh clinical evidence that its experimental Alzheimer’s drug hydromethylthionine mesylate (HMTM) could slow neurodegeneration and preserve cognition in people with early Alzheimer’s disease. The findings land just as Scottish Brain Sciences opens a state‑of‑the‑art Alzheimer’s clinical research centre across town at ONE BioHub, and as policymakers ramp up support for brain‑health innovation across the country.
Together, they point to a bigger story: Scotland’s brain‑health ecosystem is moving rapidly from theory to practice.
An oral drug that targets tau, not amyloid
TauRx has spent more than two decades pursuing a radical idea in Alzheimer’s drug development: if you can stop the abnormal tau protein inside brain cells from aggregating, you may be able to slow the disease itself. Its lead candidate, hydromethylthionine mesylate, is an oral tau aggregation inhibitor designed for people at the earliest clinically detectable stage of Alzheimer’s.
The company’s latest paper, published in The Journal of Prevention of Alzheimer’s Disease, re‑examines outcomes from patients who received HMTM 16 mg/day in its global LUCIDITY Phase III trial. The original study used a low‑dose active control rather than a true placebo to preserve blinding, because HMTM causes slight urinary discoloration. That design choice later created a problem: the “placebo” turned out to have some pharmacological activity, masking the true treatment effect.
To address this, TauRx’s analytics team built a new comparison using carefully matched external placebo groups. The latest study compared data from HMTM‑treated participants with controls drawn from the FDA‑sponsored Critical Path for Alzheimer’s Disease (CPAD) database and other external populations meeting the same key inclusion and exclusion criteria. The paper, titled Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data, reports statistically significant differences in favour of HMTM across three separate control cohorts, and concludes that “unmeasured confounding is highly unlikely to explain the observed results.”
The new analysis supports an earlier publication which found that HMTM “halted progression of neurodegeneration in Alzheimer’s disease” and that participants with Mild Cognitive Impairment who received 16 mg/day experienced “statistically significant cognitive improvement over 18 months.” Those participants “displayed no evidence of statistically significant cognitive or functional decline over a period of two years,” suggesting sustained benefit when the drug is given early.
Prof Bjoern Schelter, TauRx’s Chief Analytics Officer and lead author of the new paper, said: “The latest results strongly support the effectiveness of HMTM in people living with MCI and mild to moderate dementia due to AD.” He added: “By comparing participants receiving HMTM 16 mg/day with external control populations, we have been able to navigate the blinding problem and so demonstrate consistent and clinically meaningful differences in cognitive decline (ADAS‑Cog13) and rate of loss of brain volume at 78 and 104 weeks, as well as a global measure of progression of dementia (CDR‑SB) over 104 weeks.”
Prof Schelter said the new findings align closely with previous reports from the LUCIDITY programme: “The latest results are consistent with our earlier report demonstrating that HMTM could have significant treatment effects on neurodegeneration, tau pathology and brain atrophy. The totality of the evidence now available reinforces our belief that HMTM has the potential to offer an accessible oral treatment option which could be delivered safely and with minimal patient/physician burden.”
Safety remains a key differentiator. The original LUCIDITY trial confirmed that HMTM has a “benign safety profile,” with headache (1.5%) and diarrhoea (1.2%) the most frequent adverse effects at the 16 mg/day dose. And unlike several of the injectable anti‑amyloid antibodies that have reached the market, the roughly 3,000 participants exposed to HMTM to date have not shown increased rates of amyloid‑related imaging abnormalities on brain scans.
HMTM is still an investigational drug. A Marketing Authorisation Application from TauRx Therapeutics Management Ltd is currently being evaluated by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). If approved, the therapy would be one of the first oral, tau‑targeting, disease‑modifying treatments for Alzheimer’s disease – and one developed from the ground up in north‑east Scotland.
ONE BioHub and the rise of Aberdeen’s brain‑health cluster
TauRx is not working in isolation. Just a few hundred metres away on Aberdeen’s Foresterhill Health Campus, ONE BioHub has emerged as a focal point for the region’s life‑sciences ambitions. The £40 million innovation hub, backed by Opportunity North East, the UK and Scottish Governments and Scottish Enterprise, provides lab and office space for start‑ups, spin‑outs and scaling companies tackling global health challenges.
Alzheimer’s and brain health are central to that mission. In late 2025, Scottish Brain Sciences (SBS) – a clinical research organisation focused on early detection and treatment of neurodegenerative conditions – opened a new state‑of‑the‑art Alzheimer’s clinical research centre at ONE BioHub. The facility includes consulting rooms, laboratories and offices, and is designed to make it much easier for people in the north‑east living with Alzheimer’s, or concerned about memory problems, to join clinical studies.
The centre forms part of SBS’s IONA longitudinal cohort study, which is recruiting thousands of participants into one of the world’s largest brain‑health research communities. According to SBS, IONA is recruiting “ten times faster than any study of its kind before,” thanks in part to its multi‑site presence in Aberdeen, Edinburgh and St Andrews and its close integration with NHS services and local universities. That combination of scale and speed gives Scotland a powerful asset for testing new diagnostics, digital tools and therapies – including, in time, drugs like HMTM.
Scottish Enterprise has backed the vision with significant capital, contributing £2 million towards the construction of ONE BioHub and a further £500,000 for the fit‑out of the second floor that SBS now occupies. “It’s brilliant news that Scottish Brain Sciences has a new research facility in Aberdeen in addition to its sites in Edinburgh and St Andrews, as it carries out transformative work around diseases like Alzheimer’s,” said Jane Martin, Managing Director of Innovation and Investment at Scottish Enterprise.
TauRx itself has cited the BioHub and the wider Aberdeen cluster as important factors in its ability to attract major international investment, including a US$119 million raise triggered by Phase III trial results in 2022. For local leaders, the convergence of drug development, clinical research infrastructure and entrepreneurial support is exactly what the region set out to achieve.
From prevention apps to global conferences: a national ecosystem
Zooming out, brain health is becoming a national priority well beyond Aberdeen. Scotland’s Life Sciences Strategy, refreshed in 2025, sets a target of building a £25 billion sector by 2035 and highlights neurodegeneration, healthy ageing and data‑driven medicine as key areas of opportunity. Dementia, now the UK’s biggest killer, sits at the intersection of all three.
On the prevention side, Scottish innovators are bringing brain health into everyday life. A new NHS‑supported app called Aging Well, developed with funding from the Chief Scientist’s Office and the Scottish Health Industry Partnership, offers people across Scotland tools to track long‑term conditions, medications and lifestyle risk factors while providing practical guidance on dementia prevention. The app draws on a growing body of evidence – including a recent Lancet Commission estimate that up to 45% of dementia cases could be prevented by tackling 14 modifiable risk factors – to encourage small daily actions around blood pressure, physical activity, diet and social connection.
Research networks are also strengthening. The Scottish Cognitive Ageing Network brings together scientists from across the country to share the latest findings on cognitive ageing and brain health, with its 2025 conference in Glasgow focused on translating lab discoveries into interventions that can be deployed in clinics and communities.
In May 2026, Edinburgh will host the inaugural International Brain Health Conference, convened by Scottish Brain Sciences. The event will gather researchers, clinicians and policymakers from around the world to discuss how to “protect brain health before dementia develops,” with a strong emphasis on early detection, risk stratification and scalable models of care. “We now have the scientific tools to identify risk and disease processes long before dementia presents clinically,” said Professor Craig Ritchie, CEO and Founder of SBS and Professor of Brain Health and Neurodegenerative Medicine at the University of St Andrews. “The challenge is integrating this knowledge into services, policy, and real‑world practice. IBHC 2026 is designed to address exactly that.”
A testbed for the future of dementia care
Put together, TauRx’s emerging data on HMTM, the expansion of clinical infrastructure at ONE BioHub, and the wave of national brain‑health initiatives suggest Scotland is positioning itself as a live testbed for the future of dementia care.
If MHRA regulators give HMTM the green light, Scotland could be one of the first places in the world where an oral, tau‑targeting Alzheimer’s drug is deployed at scale in real‑world settings, supported by purpose‑built clinical research centres and digital tools that help people manage their brain‑health risk. Even if the path to approvals takes longer, the foundation being laid – from long‑term cohort studies to entrepreneurial infrastructure at ONE BioHub – is likely to benefit a generation of new diagnostics, apps and therapies.
